中国组织工程研究 ›› 2015, Vol. 19 ›› Issue (2): 262-266.doi: 10.3969/j.issn.2095-4344.2015.02.019

• 组织构建临床实践 clinical practice in tissue construction • 上一篇    下一篇

肾移植后肺部感染治疗中免疫抑制剂的应用

杨其顺,张  琳,张志强,姜  伟,龙  伟,裴向克   

  1. 解放军第281医院肾脏移植中心,河北省秦皇岛市  066100
  • 收稿日期:2014-12-22 出版日期:2015-01-08 发布日期:2015-01-08
  • 作者简介:杨其顺,男,1981年生,山东省巨野县人,汉族,2006年解放军第四军医大学毕业,主治医师,主要从事肾脏临床研究。

Immunosuppressant therapy for pulmonary infection after kidney transplantation

Yang Qi-shun, Zhang Lin, Zhang Zhi-qiang, Jiang Wei, Long Wei, Pei Xiang-ke   

  1. Center of Kidney Transplantation, the 281st Hospital of PLA, Qinhuangdao 066100, Hebei Province, China
  • Received:2014-12-22 Online:2015-01-08 Published:2015-01-08
  • About author:Yang Qi-shun, Attending physician, Center of Kidney Transplantation, the 281st Hospital of PLA, Qinhuangdao 066100, Hebei Province, China

摘要:

背景:肾移植后肺部感染病情进展快,重症肺炎死亡率高,对其进行早期诊断及治疗具有重要意义,但部分患者因免疫抑制剂的调整,出现移植肾功能受损。
目的:探讨肾移植后肺部感染治疗过程中免疫抑制剂的应用方案。
方法:回顾分析85例肺部感染的肾移植患者的临床资料。肺部感染发生于肾移植后1-6个月43例(其中2-4个月39例),6-12个月7例,12-24个月7例,24-36个月6例,大于36个月22例。根据患者病情,予以调整免疫抑制剂,联合应用小剂量激素抗炎保护移植肾功能,针对病原学抗感染,呼吸衰竭者给予呼吸机辅助呼吸,同时予以降温及营养支持等对症治疗。肺部感染早期减少或停用免疫抑制44例,进展期减少或调整免疫制剂19例,重症肺炎期停用免疫抑制剂5例,肺炎早期及进展期逐步调整免疫抑制15例,肺炎早期减量至重症肺炎停用免疫抑制剂2例。减少或停用免疫抑制剂3-51 d,平均10.7 d。
结果与结论:85例患者中治愈81例,死亡4例。4例死亡病例中,2例死于急性呼吸衰竭,2例死于多器官功能衰竭。治愈的81例中出现急性排异反应3例,移植肾功能受损6例。结果提示,肾移植后肺部感染短时间减少或停用免疫抑制剂,有利于提高治愈率,减少死亡率,及时恢复免疫制剂的应用,能有效保护移植肾功能,尤其是移植肾功能不全患者,肺部炎症进展控制住,及时恢复免疫抑制,在保护移植肾功能的意义更大。



中国组织工程研究
杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松组织工程


全文链接:

关键词: 组织构建, 组织工程, 肾移植, 肺部感染, 免疫抑制剂

Abstract:

BACKGROUND: Pulmonary infection after kidney transplantation evolves rapidly. There is a high mortality rate in patients with server pulmonary infection. It has the important significance of early diagnosis and treatment of pulmonary infection, but some patients appear to have impaired kidney function because of the adjustment of immunosuppressants.
OBJECTIVE: To explore the approaches to applying the immunosuppressants during the treatment of pulmonary infection after kidney transplantation.
METHODS: The clinical data of 85 kidney transplantation patients who suffered from pulmonary infection were retrospectively analyzed. There were 43 cases in which the infection occurred within 1-6 months after kidney transplantation, 39 of which within 2-4 months; 7 cases of infection occurring within 6-12 months; 7 cases of infection within 12-24 months; 6 cases of infection within 24-36 months; 22 cases of infection occurring beyond 36 months. The immunosuppressant dose was adjusted based on a per-case basis. As a complement, the small-dose hormone was used for anti-inflammation. Etiological treatments for resisting infections were also conducted accordingly. Ventilators were utilized for patients with respiratory failures. The body temperature of patients was monitored and controlled. Appropriate nutrition support was also provided accordingly. There were 44 cases of decreasing or stopping the use of immunosuppressants during the early period of pulmonary infection; 19 cases of decreasing or stopping the use of immunosuppressants during the treatment of pulmonary infection; 5 cases of stopping the use of immunosuppressants during the period of severe pneumonia; 15 cases of gradually changing the dose of immunosuppressants during the early and progressive period of pneumonia; 2 cases of decreasing the use during the early period of pneumonia and stopping the use during the period of severe pneumonia. The duration of decreasing or stopping the use of immunosuppressants ranged from 3-51 days, with an average of 10.7 days.
RESULTS AND CONCLUSION: Among the 85 patients, there were 81 cases cured and 4 cases of death. Among the four death cases, two cases died of acute respiratory failure and two cases died of multiple organ failure. Of the cured 81 cases, acute rejection occurred in 3 cases, while renal allograft dysfunction occurred in 6 cases. Decreasing or temporarily stopping the use of immunosuppressants during the treatment of pulmonary infection caused by the kidney transplantation increases the cure rate and decreases the mortality rate; while timely resuming the usage of immunosuppressants effectively protects the renal graft function, especially for patients with renal graft dysfunction.



中国组织工程研究
杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松组织工程


全文链接:

Key words: Kidney Transplantation, Lung, Infection, Immunosuppressive-Agents

中图分类号: